{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:13:13Z","timestamp":1790179993233,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T00:00:00Z","timestamp":1509926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T00:00:00Z","timestamp":1509926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cannabidiol (CBD) and \u2206<jats:sup>9<\/jats:sup>-tetrahydrocannabinol (THC) have well documented immunomodulatory effects <jats:italic>in vitro<\/jats:italic>, but not following oral administration in humans. Here we show that oral co-administration of cannabinoids with lipids can substantially increase their intestinal lymphatic transport in rats. CBD concentrations in the lymph were 250-fold higher than in plasma, while THC concentrations in the lymph were 100-fold higher than in plasma. Since cannabinoids are currently in clinical use for the treatment of spasticity in multiple sclerosis (MS) patients and to alleviate nausea and vomiting associated with chemotherapy in cancer patients, lymphocytes from those patients were used to assess the immunomodulatory effects of cannabinoids. The levels of cannabinoids recovered in the intestinal lymphatic system, but not in plasma, were substantially above the immunomodulatory threshold in murine and human lymphocytes. CBD showed higher immunosuppressive effects than THC. Moreover, immune cells from MS patients were more susceptible to the immunosuppressive effects of cannabinoids than those from healthy volunteers or cancer patients. Therefore, administering cannabinoids with a high-fat meal or in lipid-based formulations has the potential to be a therapeutic approach to improve the treatment of MS, or indeed other autoimmune disorders. However, intestinal lymphatic transport of cannabinoids in immunocompromised patients requires caution.<\/jats:p>","DOI":"10.1038\/s41598-017-15026-z","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T11:31:29Z","timestamp":1509449489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation"],"prefix":"10.1038","volume":"7","author":[{"given":"Atheer","family":"Zgair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Bong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5660-7256","authenticated-orcid":false,"given":"Jonathan C. M.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiaa A.","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehan","family":"Aram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Di Virgilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua W.","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Kit","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo M.","family":"Hennig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6900-9474","authenticated-orcid":false,"given":"David A.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cris S.","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3136-0933","authenticated-orcid":false,"given":"Pavel","family":"Gershkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,6]]},"reference":[{"key":"15026_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10681-004-4756-9","volume":"140","author":"RG Pertwee","year":"2004","unstructured":"Pertwee, R. G. Pharmacological and therapeutic targets for \u03949 tetrahydrocannabinol and cannabidiol. Euphytica \n                           140, 73\u201382 (2004).","journal-title":"Euphytica"},{"key":"15026_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.autrev.2016.02.008","volume":"15","author":"V Katchan","year":"2016","unstructured":"Katchan, V., David, P. & Shoenfeld, Y. Cannabinoids and autoimmune diseases: A systematic review. Autoimmunity reviews \n                           15, 513\u2013528, https:\/\/doi.org\/10.1016\/j.autrev.2016.02.008 (2016).","journal-title":"Autoimmunity reviews"},{"key":"15026_CR3","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/j.1476-5381.2011.01379.x","volume":"163","author":"E Kozela","year":"2011","unstructured":"Kozela, E. et al. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL\/6 mice. Br. J. Pharmacol. \n                           163, 1507\u20131519, https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01379.x (2011).","journal-title":"Br. J. Pharmacol."},{"key":"15026_CR4","doi-asserted-by":"publisher","first-page":"9561","DOI":"10.1073\/pnas.160105897","volume":"97","author":"AM Malfait","year":"2000","unstructured":"Malfait, A. M. et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA \n                           97, 9561\u20139566, https:\/\/doi.org\/10.1073\/pnas.160105897 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"15026_CR5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.neuropharm.2007.06.029","volume":"54","author":"L Weiss","year":"2008","unstructured":"Weiss, L. et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology \n                           54, 244\u2013249, https:\/\/doi.org\/10.1016\/j.neuropharm.2007.06.029 (2008).","journal-title":"Neuropharmacology"},{"key":"15026_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0041-008X(03)00010-3","volume":"188","author":"TR Jan","year":"2003","unstructured":"Jan, T. R., Farraj, A. K., Harkema, J. R. & Kaminski, N. E. Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A\/J mice. Toxicology and applied pharmacology \n                           188, 24\u201335 (2003).","journal-title":"Toxicology and applied pharmacology"},{"key":"15026_CR7","doi-asserted-by":"publisher","first-page":"e18281","DOI":"10.1371\/journal.pone.0018281","volume":"6","author":"VL Hegde","year":"2011","unstructured":"Hegde, V. L., Nagarkatti, P. S. & Nagarkatti, M. Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol. PLoS One \n                           6, e18281, https:\/\/doi.org\/10.1371\/journal.pone.0018281 (2011).","journal-title":"PLoS One"},{"key":"15026_CR8","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00109-009-0512-x","volume":"87","author":"F Borrelli","year":"2009","unstructured":"Borrelli, F. et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med (Berl) \n                           87, 1111\u20131121, https:\/\/doi.org\/10.1007\/s00109-009-0512-x (2009).","journal-title":"J Mol Med (Berl)"},{"key":"15026_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0165-5728(89)90075-1","volume":"23","author":"W Lyman","year":"1989","unstructured":"Lyman, W., Sonett, J., Brosnan, C., Elkin, R. & Bornstein, M. \u0394 9-Tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. Journal of neuroimmunology \n                           23, 73\u201381 (1989).","journal-title":"Journal of neuroimmunology"},{"key":"15026_CR10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S1567-5769(01)00003-0","volume":"1","author":"X Li","year":"2001","unstructured":"Li, X., Kaminski, N. E. & Fischer, L. J. Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes. Int Immunopharmacol \n                           1, 699\u2013712 (2001).","journal-title":"Int Immunopharmacol"},{"key":"15026_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/08916930500356674","volume":"39","author":"L Weiss","year":"2006","unstructured":"Weiss, L. et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity \n                           39, 143\u2013151, https:\/\/doi.org\/10.1080\/08916930500356674 (2006).","journal-title":"Autoimmunity"},{"key":"15026_CR12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.bcp.2008.06.022","volume":"76","author":"BL Kaplan","year":"2008","unstructured":"Kaplan, B. L., Springs, A. E. & Kaminski, N. E. The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochem. Pharmacol. \n                           76, 726\u2013737, https:\/\/doi.org\/10.1016\/j.bcp.2008.06.022 (2008).","journal-title":"Biochem. Pharmacol."},{"key":"15026_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jneuroim.2008.12.004","volume":"207","author":"M Jenny","year":"2009","unstructured":"Jenny, M., Santer, E., Pirich, E., Schennach, H. & Fuchs, D. Delta9-tetrahydrocannabinol and cannabidiol modulate mitogen-induced tryptophan degradation and neopterin formation in peripheral blood mononuclear cells in vitro. J. Neuroimmunol. \n                           207, 75\u201382, https:\/\/doi.org\/10.1016\/j.jneuroim.2008.12.004 (2009).","journal-title":"J. Neuroimmunol."},{"key":"15026_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0165-5728(03)00045-6","volume":"137","author":"J Killestein","year":"2003","unstructured":"Killestein, J. et al. Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis. J. Neuroimmunol. \n                           137, 140\u2013143 (2003).","journal-title":"J. Neuroimmunol."},{"key":"15026_CR15","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1365-2249.2005.02803.x","volume":"140","author":"S Katona","year":"2005","unstructured":"Katona, S., Kaminski, E., Sanders, H. & Zajicek, J. Cannabinoid influence on cytokine profile in multiple sclerosis. Clin. Exp. Immunol. \n                           140, 580\u2013585, https:\/\/doi.org\/10.1111\/j.1365-2249.2005.02803.x (2005).","journal-title":"Clin. Exp. Immunol."},{"key":"15026_CR16","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/0091-3057(93)90194-X","volume":"44","author":"RD Mattes","year":"1993","unstructured":"Mattes, R. D., Shaw, L. M., Edling-Owens, J., Engelman, K. & Elsohly, M. A. Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol. Biochem. Behav. \n                           44, 745\u2013747 (1993).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"15026_CR17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/0006-2952(80)90532-8","volume":"29","author":"AJ Siemens","year":"1980","unstructured":"Siemens, A. J., Walczak, D. & Buckley, F. E. Characterization of blood disappearance and tissue distribution of [3H]cannabidiol. Biochemical pharmacology \n                           29, 462\u2013464 (1980).","journal-title":"Biochemical pharmacology"},{"key":"15026_CR18","first-page":"3448","volume":"8","author":"A Zgair","year":"2016","unstructured":"Zgair, A. et al. Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. American journal of translational research \n                           8, 3448\u20133459 (2016).","journal-title":"American journal of translational research"},{"key":"15026_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ejps.2007.04.006","volume":"31","author":"P Gershkovich","year":"2007","unstructured":"Gershkovich, P., Qadri, B., Yacovan, A., Amselem, S. & Hoffman, A. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220. Eur. J. Pharm. Sci. \n                           31, 298\u2013305, https:\/\/doi.org\/10.1016\/j.ejps.2007.04.006 (2007).","journal-title":"Eur. J. Pharm. Sci."},{"key":"15026_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ejps.2004.12.006","volume":"24","author":"A Dahan","year":"2005","unstructured":"Dahan, A. & Hoffman, A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur. J. Pharm. Sci. \n                           24, 381\u2013388, https:\/\/doi.org\/10.1016\/j.ejps.2004.12.006 (2005).","journal-title":"Eur. J. Pharm. Sci."},{"key":"15026_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1021\/js950221g","volume":"85","author":"CJ Porter","year":"1996","unstructured":"Porter, C. J., Charman, S. A. & Charman, W. N. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion. J. Pharm. Sci. \n                           85, 351\u2013356, https:\/\/doi.org\/10.1021\/js950221g (1996).","journal-title":"J. Pharm. Sci."},{"key":"15026_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/2049-1891-4-27","volume":"4","author":"MR Ruth","year":"2013","unstructured":"Ruth, M. R. & Field, C. J. The immune modifying effects of amino acids on gut-associated lymphoid tissue. Journal of animal science and biotechnology \n                           4, 27, https:\/\/doi.org\/10.1186\/2049-1891-4-27 (2013).","journal-title":"Journal of animal science and biotechnology"},{"issue":"Suppl 1","key":"15026_CR23","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1079\/BJN20041357","volume":"93","author":"B Watzl","year":"2005","unstructured":"Watzl, B., Girrbach, S. & Roller, M. Inulin, oligofructose and immunomodulation. The British journal of nutrition \n                           93(Suppl 1), S49\u201355 (2005).","journal-title":"The British journal of nutrition"},{"key":"15026_CR24","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/j.1440-1746.1998.tb00602.x","volume":"13","author":"S Miura","year":"1998","unstructured":"Miura, S., Tsuzuki, Y., Hokari, R. & Ishii, H. Modulation of intestinal immune system by dietary fat intake: relevance to Crohn\u2019s disease. Journal of gastroenterology and hepatology \n                           13, 1183\u20131190 (1998).","journal-title":"Journal of gastroenterology and hepatology"},{"key":"15026_CR25","doi-asserted-by":"crossref","unstructured":"Wright, S. & Guy, G. Licensed Cannabis-Based Medicines: Benefits and Risks. Handbook of Cannabis, 373 (2014).","DOI":"10.1093\/acprof:oso\/9780199662685.003.0020"},{"key":"15026_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/cpt.108","volume":"97","author":"DI Abrams","year":"2015","unstructured":"Abrams, D. I. & Guzman, M. Cannabis in cancer care. Clinical pharmacology and therapeutics \n                           97, 575\u2013586, https:\/\/doi.org\/10.1002\/cpt.108 (2015).","journal-title":"Clinical pharmacology and therapeutics"},{"key":"15026_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/jcla.1860090203","volume":"9","author":"R de Fries","year":"1995","unstructured":"de Fries, R. & Mitsuhashi, M. Quantification of mitogen induced human lymphocyte proliferation: comparison of alamarBlue assay to 3H-thymidine incorporation assay. J. Clin. Lab. Anal. \n                           9, 89\u201395 (1995).","journal-title":"J. Clin. Lab. Anal."},{"key":"15026_CR28","doi-asserted-by":"crossref","unstructured":"Zgair, A., Wong, J. C. M. & Gershkovich, P. In Neuro-Immuno-Gastroenterology (eds Cris Constantinescu, Razvan Arsenescu, & Violeta Arsenescu) 237-261 (Springer International Publishing, 2016).","DOI":"10.1007\/978-3-319-28609-9_14"},{"key":"15026_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2013.12.031","volume":"177","author":"S Han","year":"2014","unstructured":"Han, S. et al. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies. Journal of controlled release: official journal of the Controlled Release Society \n                           177, 1\u201310, https:\/\/doi.org\/10.1016\/j.jconrel.2013.12.031 (2014).","journal-title":"Journal of controlled release: official journal of the Controlled Release Society"},{"key":"15026_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(01)00150-8","volume":"50","author":"MA Swartz","year":"2001","unstructured":"Swartz, M. A. The physiology of the lymphatic system. Adv. Drug. Deliv. Rev. \n                           50, 3\u201320 (2001).","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"15026_CR31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1089\/jir.2011.0065","volume":"31","author":"KD Moudgil","year":"2011","unstructured":"Moudgil, K. D. & Choubey, D. Cytokines in autoimmunity: role in induction, regulation, and treatment. J. Interferon Cytokine Res. \n                           31, 695\u2013703, https:\/\/doi.org\/10.1089\/jir.2011.0065 (2011).","journal-title":"J. Interferon Cytokine Res."},{"key":"15026_CR32","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s11481-013-9485-1","volume":"8","author":"RH Robinson","year":"2013","unstructured":"Robinson, R. H. et al. Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction. Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology \n                           8, 1239\u20131250, https:\/\/doi.org\/10.1007\/s11481-013-9485-1 (2013).","journal-title":"Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology"},{"key":"15026_CR33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/0091-3057(91)90357-8","volume":"40","author":"P Consroe","year":"1991","unstructured":"Consroe, P., Kennedy, K. & Schram, K. Assay of plasma cannabidiol by capillary gas chromatography\/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol. Biochem. Behav. \n                           40, 517\u2013522 (1991).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"15026_CR34","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.2174\/138161212802884780","volume":"18","author":"R Martin-Santos","year":"2012","unstructured":"Martin-Santos, R. et al. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr. Pharm. Des. \n                           18, 4966\u20134979 (2012).","journal-title":"Curr. Pharm. Des."},{"key":"15026_CR35","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1021\/mp100259a","volume":"7","author":"NL Trevaskis","year":"2010","unstructured":"Trevaskis, N. L., Charman, W. N. & Porter, C. J. Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation? Molecular pharmaceutics \n                           7, 2297\u20132309, https:\/\/doi.org\/10.1021\/mp100259a (2010).","journal-title":"Molecular pharmaceutics"},{"key":"15026_CR36","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ejps.2005.07.011","volume":"26","author":"P Gershkovich","year":"2005","unstructured":"Gershkovich, P. & Hoffman, A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur. J. Pharm. Sci. \n                           26, 394\u2013404, https:\/\/doi.org\/10.1016\/j.ejps.2005.07.011 (2005).","journal-title":"Eur. J. Pharm. Sci."},{"key":"15026_CR37","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejps.2011.04.011","volume":"43","author":"M Sun","year":"2011","unstructured":"Sun, M. et al. Intestinal absorption and intestinal lymphatic transport of sirolimus from self-microemulsifying drug delivery systems assessed using the single-pass intestinal perfusion (SPIP) technique and a chylomicron flow blocking approach: linear correlation with oral bioavailabilities in rats. Eur. J. Pharm. Sci. \n                           43, 132\u2013140, https:\/\/doi.org\/10.1016\/j.ejps.2011.04.011 (2011).","journal-title":"Eur. J. Pharm. Sci."},{"issue":"Pt 3","key":"15026_CR38","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1042\/bj2980605","volume":"298","author":"PC Calder","year":"1994","unstructured":"Calder, P. C., Yaqoob, P. & Newsholme, E. A. Triacylglycerol metabolism by lymphocytes and the effect of triacylglycerols on lymphocyte proliferation. The Biochemical journal \n                           298(Pt 3), 605\u2013611 (1994).","journal-title":"The Biochemical journal"},{"key":"15026_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/apha.12474","volume":"214","author":"L Jean-Gilles","year":"2015","unstructured":"Jean-Gilles, L. et al. Effects of pro-inflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cells. Acta Physiol (Oxf) \n                           214, 63\u201374, https:\/\/doi.org\/10.1111\/apha.12474 (2015).","journal-title":"Acta Physiol (Oxf)"},{"key":"15026_CR40","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nm1561","volume":"13","author":"K Maresz","year":"2007","unstructured":"Maresz, K. et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med. \n                           13, 492\u2013497, https:\/\/doi.org\/10.1038\/nm1561 (2007).","journal-title":"Nat. Med."},{"key":"15026_CR41","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1189\/jlb.0508282","volume":"84","author":"AE Springs","year":"2008","unstructured":"Springs, A. E., Karmaus, P. W., Crawford, R. B., Kaplan, B. L. & Kaminski, N. E. Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol. J. Leukoc. Biol. \n                           84, 1574\u20131584, https:\/\/doi.org\/10.1189\/jlb.0508282 (2008).","journal-title":"J. Leukoc. Biol."},{"key":"15026_CR42","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1182\/blood.V84.7.2221.2221","volume":"84","author":"CL Mackall","year":"1994","unstructured":"Mackall, C. L. et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood \n                           84, 2221\u20132228 (1994).","journal-title":"Blood"},{"key":"15026_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nri702","volume":"2","author":"JJ O\u2032Shea","year":"2002","unstructured":"O\u2032Shea, J. J., Ma, A. & Lipsky, P. Cytokines and autoimmunity. Nature reviews. Immunology \n                           2, 37\u201345, https:\/\/doi.org\/10.1038\/nri702 (2002).","journal-title":"Nature reviews. Immunology"},{"key":"15026_CR44","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/ni.2044","volume":"12","author":"MJ McGeachy","year":"2011","unstructured":"McGeachy, M. J. GM-CSF: the secret weapon in the TH17 arsenal. Nature immunology \n                           12, 521\u2013522 (2011).","journal-title":"Nature immunology"},{"key":"15026_CR45","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/ni.2031","volume":"12","author":"M El-Behi","year":"2011","unstructured":"El-Behi, M. et al. The encephalitogenicity of TH17 cells is dependent on IL-1-and IL-23-induced production of the cytokine GM-CSF. Nature immunology \n                           12, 568\u2013575 (2011).","journal-title":"Nature immunology"},{"key":"15026_CR46","doi-asserted-by":"publisher","first-page":"241ra280","DOI":"10.1126\/scitranslmed.3008706","volume":"6","author":"R Noster","year":"2014","unstructured":"Noster, R. et al. IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Science translational medicine \n                           6, 241ra280, https:\/\/doi.org\/10.1126\/scitranslmed.3008706 (2014).","journal-title":"Science translational medicine"},{"key":"15026_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6056","volume":"5","author":"FJ Hartmann","year":"2014","unstructured":"Hartmann, F. J. et al. Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells. Nature communications \n                           5, 5056, https:\/\/doi.org\/10.1038\/ncomms6056 (2014).","journal-title":"Nature communications"},{"key":"15026_CR48","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/0192-0561(91)90160-9","volume":"13","author":"B Watzl","year":"1991","unstructured":"Watzl, B., Scuderi, P. & Watson, R. R. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int. J. Immunopharmacol. \n                           13, 1091\u20131097 (1991).","journal-title":"Int. J. Immunopharmacol."},{"key":"15026_CR49","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/157488611798280924","volume":"6","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi, M. M., Queiroz, R. H., Zuardi, A. W. & Crippa, J. A. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Current drug safety \n                           6, 237\u2013249 (2011).","journal-title":"Current drug safety"},{"key":"15026_CR50","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/sj.embor.7401099","volume":"8","author":"MF Bachmann","year":"2007","unstructured":"Bachmann, M. F. & Oxenius, A. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO reports \n                           8, 1142\u20131148, https:\/\/doi.org\/10.1038\/sj.embor.7401099 (2007).","journal-title":"EMBO reports"},{"key":"15026_CR51","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fimmu.2013.00010","volume":"4","author":"T Ito","year":"2013","unstructured":"Ito, T., Connett, J. M., Kunkel, S. L. & Matsukawa, A. The linkage of innate and adaptive immune response during granulomatous development. Frontiers in immunology \n                           4, 10, https:\/\/doi.org\/10.3389\/fimmu.2013.00010 (2013).","journal-title":"Frontiers in immunology"},{"key":"15026_CR52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jneuroim.2005.04.023","volume":"166","author":"JL Croxford","year":"2005","unstructured":"Croxford, J. L. & Yamamura, T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J. Neuroimmunol. \n                           166, 3\u201318, https:\/\/doi.org\/10.1016\/j.jneuroim.2005.04.023 (2005).","journal-title":"J. Neuroimmunol."},{"key":"15026_CR53","doi-asserted-by":"publisher","DOI":"10.3791\/2966","author":"CM Parkinson","year":"2011","unstructured":"Parkinson, C. M. et al. Diagnostic necropsy and selected tissue and sample collection in rats and mice. Journal of visualized experiments: JoVE. https:\/\/doi.org\/10.3791\/2966 (2011).","journal-title":"Journal of visualized experiments: JoVE"},{"key":"15026_CR54","unstructured":"Janossy, G. & Greaves, M. F. Lymphocyte Activation .1. Response of T and B Lymphocytes to Phytomitogens. Clin. Exp. Immunol. 9, 483-& (1971)."},{"key":"15026_CR55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jpba.2015.05.019","volume":"114","author":"A Zgair","year":"2015","unstructured":"Zgair, A. et al. Development of a simple and sensitive HPLC-UV method for the simultaneous determination of cannabidiol and Delta(9)-tetrahydrocannabinol in rat plasma. J. Pharm. Biomed. Anal. \n                           114, 145\u2013151, https:\/\/doi.org\/10.1016\/j.jpba.2015.05.019 (2015).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"15026_CR56","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1021\/acs.molpharmaceut.6b00597","volume":"13","author":"P Benito-Gallo","year":"2016","unstructured":"Benito-Gallo, P., Marlow, M., Zann, V., Scholes, P. & Gershkovich, P. Linking in Vitro Lipolysis and Microsomal Metabolism for the Quantitative Prediction of Oral Bioavailability of BCS II Drugs Administered in Lipidic Formulations. Molecular pharmaceutics \n                           13, 3526\u20133540, https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00597 (2016).","journal-title":"Molecular pharmaceutics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15026-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15026-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15026-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T13:04:26Z","timestamp":1671800666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15026-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,6]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["15026"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-15026-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,6]]},"assertion":[{"value":"27 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14542"}}